Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | RAPGEF4 | Q8WZA2 | 7/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.39 |
| ▸ | PGR | P06401 | 3/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746886 | 0.81 | NR3C1 (0.36) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL7515730 | 0.76 | L3MBTL1 (0.41) | NR3C1PGRNR3C2LMNASMN1; SMN2 | |
| SCHEMBL7374081 | 0.74 | SLC1A3 (0.45) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL10050619 | 0.74 | L3MBTL1 (0.55) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL7515798 | 0.74 | L3MBTL1 (0.40) | NR3C1PGRNR3C2LMNASMN1; SMN2 | |
| SCHEMBL4746084 | 0.72 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL27271507 | 0.71 | CA1 (0.45) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL5887639 | 0.71 | F2 (0.36) | F2PRSS1PRSS2PRSS3CA1 | |
| Hydroxyamine SCHEMBL259333 | 0.70 | CA1 (0.54) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL23788 | 0.69 | CA1 (0.58) | F2PRSS1PRSS2PRSS3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7453011-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PROGEN PHARMACEUTICALS, INC. | 2007-12-13 | — | — | US | disclosed |
| US-7235695-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | SLIL BIOMEDICAL CORPORATION | 2007-06-26 | — | — | US | disclosed |
| US-20060030735-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | CELLGATE, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| US-6982351-B2 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | CELLGATE, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| EP-1453787-A1 | CYCLOALKYL SUBSTITUTED POLYAMINES FOR CANCER THERAPY AND METHODS OF SYNTHESIS THEREFOR | SLIL Biomedical Corporation (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030195377-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | SLIL BIOMEDICAL CORPORATION | 2003-10-16 | — | — | US | disclosed |
| WO-2003050072-A1 | CYCLOALKYL SUBSTITUTED POLYAMINES FOR CANCER THERAPY AND METHODS OF SYNTHESIS THEREFOR | SLIL BIOMEDICAL CORPORATION (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195377-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | F2 3291/4885PRSS1 1573/4885PRSS2 3513/4885 |
| US-20060030735-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | F2 3291/4885PRSS1 1573/4885PRSS2 3513/4885 |
| US-20070287754-A1 | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | PAICS, DHPS, DHFR | F2 3291/4885PRSS1 1573/4885PRSS2 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.